GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (TSXV:NGEN) » Definitions » Goodwill-to-Asset

NervGen Pharma (TSXV:NGEN) Goodwill-to-Asset : 0.00 (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. NervGen Pharma's Goodwill for the quarter that ended in Jun. 2024 was C$0.00 Mil. NervGen Pharma's Total Assets for the quarter that ended in Jun. 2024 was C$27.89 Mil.


NervGen Pharma Goodwill-to-Asset Historical Data

The historical data trend for NervGen Pharma's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma Goodwill-to-Asset Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Goodwill-to-Asset
Get a 7-Day Free Trial - - - - -

NervGen Pharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NervGen Pharma's Goodwill-to-Asset

For the Biotechnology subindustry, NervGen Pharma's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NervGen Pharma's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NervGen Pharma's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where NervGen Pharma's Goodwill-to-Asset falls into.



NervGen Pharma Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

NervGen Pharma's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Goodwill to Asset (A: Dec. 2023 )=Goodwill/Total Assets
=0/13.236
=

NervGen Pharma's Goodwill to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Goodwill to Asset (Q: Jun. 2024 )=Goodwill/Total Assets
=0/27.888
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NervGen Pharma  (TSXV:NGEN) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


NervGen Pharma Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


NervGen Pharma Business Description

Traded in Other Exchanges
Address
112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.
Executives
John Ruffolo Director
Krista Mckerracher Director
William Joseph Radvak Director
Harold Punnett 10% Security Holder, Director
Robert Pilz Senior Officer

NervGen Pharma Headlines

No Headlines